[go: up one dir, main page]

EP2540742A4 - Anti-cyr61 protein monoclonal antibodies and uses thereof - Google Patents

Anti-cyr61 protein monoclonal antibodies and uses thereof

Info

Publication number
EP2540742A4
EP2540742A4 EP10834216.3A EP10834216A EP2540742A4 EP 2540742 A4 EP2540742 A4 EP 2540742A4 EP 10834216 A EP10834216 A EP 10834216A EP 2540742 A4 EP2540742 A4 EP 2540742A4
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibodies
protein monoclonal
cyr61 protein
cyr61
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10834216.3A
Other languages
German (de)
French (fr)
Other versions
EP2540742A1 (en
Inventor
Ningli Li
Baihua Shen
Li Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Immunology
SHANGHAI INST OF IMMUNOLOGY
Original Assignee
Shanghai Institute of Immunology
SHANGHAI INST OF IMMUNOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN200910199937A external-priority patent/CN101709088A/en
Priority claimed from CN200910199938A external-priority patent/CN101709089A/en
Application filed by Shanghai Institute of Immunology, SHANGHAI INST OF IMMUNOLOGY filed Critical Shanghai Institute of Immunology
Publication of EP2540742A1 publication Critical patent/EP2540742A1/en
Publication of EP2540742A4 publication Critical patent/EP2540742A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP10834216.3A 2009-12-04 2010-11-27 Anti-cyr61 protein monoclonal antibodies and uses thereof Withdrawn EP2540742A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910199937A CN101709088A (en) 2009-12-04 2009-12-04 Monoclonal antibody for resisting Cyr61 protein and application thereof
CN200910199938A CN101709089A (en) 2009-12-04 2009-12-04 Monoclonal antibody for resisting Cyr61 protein and application thereof
PCT/CN2010/079208 WO2011066783A1 (en) 2009-12-04 2010-11-27 Anti-cyr61 protein monoclonal antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EP2540742A1 EP2540742A1 (en) 2013-01-02
EP2540742A4 true EP2540742A4 (en) 2014-02-12

Family

ID=44114613

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10834216.3A Withdrawn EP2540742A4 (en) 2009-12-04 2010-11-27 Anti-cyr61 protein monoclonal antibodies and uses thereof

Country Status (2)

Country Link
EP (1) EP2540742A4 (en)
WO (1) WO2011066783A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263852C (en) * 1996-03-15 2006-07-12 穆尼恩公司 Extracellular matrix signalling molecules
AU2001271365A1 (en) * 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
EP1322778A4 (en) * 2000-09-29 2005-06-15 Wyeth Corp Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
CN101709089A (en) * 2009-12-04 2010-05-19 上海市免疫学研究所 Monoclonal antibody for resisting Cyr61 protein and application thereof
CN101709088A (en) * 2009-12-04 2010-05-19 上海市免疫学研究所 Monoclonal antibody for resisting Cyr61 protein and application thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Cyr61 (N-16): sc-8560", XP002718211, Retrieved from the Internet <URL:http://datasheets.scbt.com/sc-8560.pdf> [retrieved on 20131219] *
ANONYMOUS: "Human Cyr61/CCN1 Antibody Monoclonal Mouse IgG1 Clone # 365108 Catalog Number: MAB4055", 6 May 2010 (2010-05-06), XP055094502, Retrieved from the Internet <URL:http://www.rndsystems.com/pdf/MAB4055.pdf> [retrieved on 20131219] *
ANONYMOUS: "new products: R&D Systems New Products March 2007", 1 March 2007 (2007-03-01), XP055094501, Retrieved from the Internet <URL:http://www.woongbee.com/0NewHome/RnD/Literature/NewPro/200703_5886.pdf> [retrieved on 20131219] *
See also references of WO2011066783A1 *
ZHANG QIUYU ET AL: "A Critical Role of Cyr61 in Interleukin-17-Dependent Proliferation of Fibroblast-like Synoviocytes in Rheumatoid Arthritis", ARTHRITIS & RHEUMATISM, JOHN WILEY & SONS, INC, US, vol. 60, no. 12, 1 December 2009 (2009-12-01), pages 3602 - 3612, XP009148188, ISSN: 0004-3591, [retrieved on 20091130], DOI: 10.1002/ART.24999 *

Also Published As

Publication number Publication date
EP2540742A1 (en) 2013-01-02
WO2011066783A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
HRP20181616T1 (en) Fully human anti-vap-1 monoclonal antibodies
HK1176940A1 (en) Monoclonal antibodies and diagnostic uses thereof
PT2510011E (en) Monoclonal antibodies that bind b7h6 and uses thereof
IL215649A (en) Anti-tnf-α monoclonal antibodies and uses thereof
IL232008A (en) Isolated alpha-4beta-7 heterodimer specific antigen binding protein and various aspects related thereto
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
EP2494062A4 (en) Anti-glp-1r antibodies and their uses
EP2525813A4 (en) Anti-ilt5 antibodies and ilt5-binding antibody fragments
IL216115A0 (en) Humanized anti-egfl7 antibodies and methods using same
HK1168871A1 (en) Monoclonal antibodies
IL215291A0 (en) NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
EP2475383A4 (en) Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
HK1158977A1 (en) Anti-ferroportin monoclonal antibodies and uses thereof
EP2484694A4 (en) Monoclonal antibody against human hig-1 polypeptide
EP2540742A4 (en) Anti-cyr61 protein monoclonal antibodies and uses thereof
IL218438A0 (en) Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/577 20060101ALI20131220BHEP

Ipc: A61P 19/04 20060101ALI20131220BHEP

Ipc: C07K 16/18 20060101AFI20131220BHEP

Ipc: A61P 29/00 20060101ALI20131220BHEP

Ipc: A61K 39/395 20060101ALI20131220BHEP

Ipc: A61P 35/00 20060101ALI20131220BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20140114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140812